Eighteen months after Gilead Sciences Inc. launched hepatitis C drug Sovaldi (sofosbuvir) at an eye-popping $84,000 per 12-week treatment course, Sovaldi has now become synonymous with a debate over drug pricing that continues to rage. But the story is no longer about the $1000-per-pill launch price of Sovaldi in the US. It’s now about how fast and furiously the cost of this medicine, and others like it, has fallen since.
Sovaldi’s launch didn’t by itself build the drug pricing fire; it simply provided the spark. The rising cost – and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?